Affimed to Review Clinical Data From Lung Cancer Trial on December 17
Affimed to Review Clinical Data From Lung Cancer Trial on December 17
Affimed将在12月17日审查肺癌临床试验的数据
Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE with atezolizumab in non-small cell lung cancer.
Affimed N.V. (纳斯达克:AFMD) ("Affimed"或"公司"), 一家致力于帮助患者恢复对抗癌症的固有能力的临床阶段免疫肿瘤学公司，今天宣布将于12月17日星期二上午8:30（东部标准时间）/ 下午2:30（中部欧洲时间）召开电话会议，以回顾AFM24-102临床数据，这是其AFM24电芯结合atezolizumab用于非小细胞肺癌的组合试验。
资讯热榜
更新时间